Shinta Mizuno

Shinta Mizuno

Auto-generated profile, based on publicly available information

Shinta Mizuno

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Digestion
Verified
Journal Article
Open access
SSShinya Sugimoto
Shinya Sugimoto
MNMakoto Naganuma
Makoto Naganuma
HKHiroki Kiyohara
Hiroki Kiyohara
MAMari Arai
Mari Arai
KOKeiko Ono
Keiko Ono
TKTakanori Kanai
Takanori Kanai
Background/Aims: Chinese herbal medicine Qing-Dai (also known as indigo naturalis) has been used to treat various inflammatory conditions. However, not much has been studied about the use of oral Qing-Dai in the treatment for ulcerative colitis (UC) patients. Studies exploring alternative treatments for UC are of considerable interest. In this study, we aimed at prospectively evaluating the safety and efficacy of Qing-Dai for UC patients. Methods: The open-label, prospective pilot study was conducted at Keio University Hospital. A total of 20 patients with moderate UC activity were enrolled. Oral Qing-Dai in capsule form was taken twice a day (daily dose, 2 g) for 8 weeks. Results: At week 8, the rates of clinical response, clinical remission, and mucosal healing were 72, 33, and 61%, respectively. The clinical and endoscopic scores, CRP levels, and fecal occult blood results were also significantly improved. We observed 2 patients with mild liver dysfunction; 1 patient discontinued due to infectious colitis and 1 patient discontinued due to mild nausea. Conclusion: This is the first prospective study indicating that oral Qing-Dai is effective for inducing remission in patients with moderate UC activity and can be tolerated. Thus, Qing-Dai may be considered an alternative treatment for patients, although further investigation is warranted.

30 January 2020 in Intestinal Research
Verified
Journal Article
Open access
PDF file
SMShinta Mizuno
Shinta Mizuno
KOKeiko Ono
Keiko Ono
YMYohei Mikami
Yohei Mikami
MNMakoto Naganuma
Makoto Naganuma
TFTomohiro Fukuda
Tomohiro Fukuda
TKTakanori Kanai
Takanori Kanai
5-Aminosalicylic acid (ASA) causes intolerance reactions in some patients. This study was performed to examine the prognosis of patients with ulcerative colitis (UC) and 5-ASA intolerance, and to evaluate the potential interaction between 5-ASA intolerance and the intestinal microbiota. We performed a retrospective cohort study of patients with UC who visited participating hospitals. The primary endpoint was to compare the incidence of hospitalization within 12 months between the 5-ASA intolerance group and the 5-ASA tolerance group. The secondary endpoint was to compare the risk of adverse clinical outcomes after the start of biologics between the 2 groups. We also assessed the correlation between 5-ASA intolerance and microbial change in an independently recruited cohort of patients with UC. Of 793 patients, 59 (7.4%) were assigned to the 5-ASA intolerance group and 734 (92.5%) were assigned to the 5-ASA tolerance group. The admission rate and incidence of corticosteroid use were significantly higher in the intolerance than tolerance group (P< 0.001). In 108 patients undergoing treatment with anti-tumor necrosis factor biologics, 5-ASA intolerance increased the incidence of additional induction therapy after starting biologics (P< 0.001). The 5-ASA intolerance group had a greater abundance of bacteria in the genera Faecalibacterium, Streptococcus, and Clostridium than the 5-ASA tolerance group (P< 0.05). In patients with UC, 5-ASA intolerance is associated with a risk of adverse clinical outcomes and dysbiosis. Bacterial therapeutic optimization of 5-ASA administration may be important for improving the prognosis of patients with UC.

1 September 2019 in Digestive and Liver Disease
Verified
Journal Article
Closed access
MMMakoto Mutaguchi
Makoto Mutaguchi
MNMakoto Naganuma
Makoto Naganuma
SSShinya Sugimoto
Shinya Sugimoto
TFTomohiro Fukuda
Tomohiro Fukuda
KNKosaku Nanki
Kosaku Nanki
TKTakanori Kanai
Takanori Kanai

1 January 2014 in The Keio Journal of Medicine
Verified
Journal Article
Open access
Katsuyoshi MatsuokaKatsuyoshi Matsuoka
Katsuyoshi Matsuoka
SMShinta Mizuno
Shinta Mizuno
AHAtsushi Hayashi
Atsushi Hayashi
THTadakazu Hisamatsu
Tadakazu Hisamatsu
MNMakoto Naganuma
Makoto Naganuma
TKTakanori Kanai
Takanori Kanai
Fecal microbiota transplantation (FMT) is a treatment to restore the normal microbial composition of the gut by introducing fecal microbiota obtained from a healthy donor into a diseased individual. There has been a growing interest in the use of FMT as a treatment of various diseases including Clostridium difficile infection (CDI), inflammatory bowel disease, and irritable bowel syndrome. Despite the increasing application of FMT, there are no standard protocols. Many aspects of FMT procedures vary regarding donor selection, preparation of fecal materials, recipient preparation, and route of administration. FMT is most successful in treating recurrent CDI. A randomized controlled trial reported a success rate of approximaetly 90%. Ulcerative colitis (UC) is a potentially good indication for FMT, although limited evidence is available on the use of FMT for the treatment of UC. Only several small case series have been reported, and the results in terms of efficacy are inconsistent. FMT can also be used to treat diseases other than gastrointestinal disorders in which the gut microbiota is disturbed, e.g., cardiovascular diseases, autoimmune diseases, and metabolic disorders. There remain many unanswered questions with regard to FMT, and more research is required in this field.

25 June 2019 in Digestion
Verified
Journal Article
Closed access
PDF file
YYYusuke Yoshimatsu
Yusuke Yoshimatsu
MNMakoto Naganuma
Makoto Naganuma
SSShinya Sugimoto
Shinya Sugimoto
STShun Tanemoto
Shun Tanemoto
SUSatoko Umeda
Satoko Umeda
TKTakanori Kanai
Takanori Kanai
Background: Indigo naturalis (IN) consists of ligands for the aryl hydrocarbon receptor and exhibits anti-inflammatory effects. Previously, we demonstrated that an 8-week treatment with oral IN is effective in inducing a clinical response in patients with ulcerative colitis (UC). Some UC patients with proctitis are refractory to topical mesalamine or corticosteroids and therefore require an alternative topical treatment. Objectives: We aimed to prospectively evaluate the safety and efficacy of IN suppositories in UC patients. Method: We performed an open-label, single-center, prospective pilot study from February 2018 to October 2018. A total of 10 patients with active UC, who had moderate to severe inflammation from the rectum to the sigmoid colon, were enrolled. The patients received a daily dose of 50 mg IN suppository for 4 weeks. The primary endpoint was safety at week 4. Results: Although 1 patient experienced anal pain, no serious adverse events were observed. At week 4, the rates of clinical remission and mucosal healing were 30 and 40%, respectively. Mayo rectal bleeding subscores significantly improved after treatment (1.80 ± 0.13 vs. 0.90 ± 0.28; p = 0.009). Approximately 80% of the patients with a baseline Mayo endoscopic subscore in the rectum (r-MES) of 2 achieved mucosal healing, but those with a baseline r-MES of 3 did not. Conclusions: We found that 4 weeks of IN suppository can be tolerated by UC patients, but its efficacy was limited by the severity of the disease. Further investigation will be needed in order to confirm the optimum dose of IN suppository for patients with UC.

15 September 2020 in Gut and Liver
Verified
Journal Article
Open access
PDF file
KTKaoru Takabayashi
Kaoru Takabayashi
NHNaoki Hosoe
Naoki Hosoe
MKMotohiko Kato
Motohiko Kato
YHYukie Hayashi
Yukie Hayashi
RMRyoichi Miyanaga
Ryoichi Miyanaga
TKTakanori Kanai
Takanori Kanai
Kaoru Takabayashi, Naoki Hosoe, Motohiko Kato, Yukie Hayashi, Ryoichi Miyanaga, Kosaku Nanki, Kayoko Fukuhara, Yohei Mikami, Shinta Mizuno, Tomohisa Sujino, Makoto Mutaguchi, Makoto Naganuma, Naohisa Yahagi, Haruhiko Ogata, and Takanori Kanai. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl19228